Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Antiribosomal P protein antibodies

Donald B Bloch, MD
Section Editor
Robert H Shmerling, MD
Deputy Editor
Monica Ramirez Curtis, MD, MPH


Autoantibodies directed against three phosphorylated protein (“P protein”) components of ribosomes are present in a minority of patients with systemic lupus erythematosus (SLE) and are highly specific for this disease. Some studies have suggested that these antibodies may serve as markers for specific disease manifestations, including central nervous system (CNS) disease and hepatitis, but other studies have not confirmed these associations. (See 'Associations with specific manifestations of SLE' below.)

The specificity, clinical associations, and utility of measuring antiribosomal P protein antibodies are discussed here. An overview of antinuclear antibodies and the approach to the diagnosis of CNS disease in SLE are presented separately. (See "Measurement and clinical significance of antinuclear antibodies" and "Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus".)


Antigen specificity — The targets of antiribosomal antibodies found in the sera of some patients with systemic lupus erythematosus (SLE) are three highly conserved phosphorylated proteins (P proteins) located on the 60S subunit of ribosomes [1,2]. The P proteins, which exhibit molecular weights of 35, 19, and 17 kD, are designated P0, P1, and P2, respectively. The immunodominant epitope in patients with SLE is a shared sequence at the carboxy (C)-termini of the P proteins [3-5].

In their native form, the ribosomal P antigens form a pentamer consisting of one copy of P0 and two copies each of P1 and P2. This complex interacts with the 28S ribosomal RNA molecule to form the ribosomal stalk, including a guanosine triphosphatase (GTPase) domain involved in the elongation step of protein translation [6]. Monoclonal antibodies to P proteins inhibit binding of elongation factor (EF)-1 alpha and EF-2 to ribosomes and inhibit protein synthesis [7,8].

P proteins were initially identified on ribosomes in the cytoplasm [9]; subsequent studies have also documented epitopes recognized by antiribosomal P protein antibodies on the surface of neuronal, hepatoma, and activated T cells in vitro [10,11]. The binding of antibodies to these proteins on cell surfaces could have pathogenic significance, given evidence that such antibodies can be internalized, resulting in cellular dysfunction [6,12].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 04, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. J Exp Med 1985; 162:459.
  2. Francoeur AM, Peebles CL, Heckman KJ, et al. Identification of ribosomal protein autoantigens. J Immunol 1985; 135:2378.
  3. Mahler M, Kessenbrock K, Raats J, et al. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med (Berl) 2003; 81:194.
  4. Elkon K, Skelly S, Parnassa A, et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1986; 83:7419.
  5. Hasler P, Brot N, Weissbach H, et al. The effect of phosphorylation and site-specific mutations in the immunodominant epitope of the human ribosomal P proteins. Clin Immunol Immunopathol 1994; 72:273.
  6. Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity 2005; 38:85.
  7. Uchiumi T, Traut RR, Kominami R. Monoclonal antibodies against acidic phosphoproteins P0, P1, and P2 of eukaryotic ribosomes as functional probes. J Biol Chem 1990; 265:89.
  8. Stacey DW, Skelly S, Watson T, et al. The inhibition of protein synthesis by IgG containing anti-ribosome P autoantibodies from systemic lupus erythematosus patients. Arch Biochem Biophys 1988; 267:398.
  9. Miyachi K, Tan EM. Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases. Arthritis Rheum 1979; 22:87.
  10. Koren E, Reichlin MW, Koscec M, et al. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest 1992; 89:1236.
  11. Hirohata S, Itoh K, Nakanishi K. Antiribosomal P protein antibody in human systemic lupus erythematosus is an antilymphocyte antibody that specifically reacts with activated T cells. (abstract) Arthritis Rheum 2000; 43:S240.
  12. Koscec M, Koren E, Wolfson-Reichlin M, et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 1997; 159:2033.
  13. Heinlen LD, Ritterhouse LL, McClain MT, et al. Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J Mol Med (Berl) 2010; 88:719.
  14. Bonfa E, Elkon KB. Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum 1986; 29:981.
  15. Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90:54.
  16. Koffler D, Miller TE, Lahita RG. Studies on the specificity and clinical correlation of antiribosomal antibodies in systemic lupus erythematosus sera. Arthritis Rheum 1979; 22:463.
  17. Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.
  18. Mahler M, Agmon-Levin N, van Liempt M, et al. Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. Rheumatol Int 2012; 32:691.
  19. Sato T, Uchiumi T, Ozawa T, et al. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991; 18:1681.
  20. van Dam A, Nossent H, de Jong J, et al. Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study. J Rheumatol 1991; 18:1026.
  21. Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006; 13:77.
  22. Nojima Y, Minota S, Yamada A, et al. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51:1053.
  23. Reichlin M, Broyles TF, Hubscher O, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 1999; 42:69.
  24. Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58:843.
  25. Hanly JG, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70:1726.
  26. Teh LS, Bedwell AE, Isenberg DA, et al. Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 1992; 51:489.
  27. Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357.
  28. Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54:312.
  29. Koren E, Schnitz W, Reichlin M. Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus. Arthritis Rheum 1993; 36:1325.
  30. Hulsey M, Goldstein R, Scully L, et al. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995; 74:252.
  31. Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995; 99:465.
  32. Haddouk S, Marzouk S, Jallouli M, et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48:953.
  33. Reichlin M, Wolfson-Reichlin M. Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. Clin Immunol 2003; 108:69.
  34. Chindalore V, Neas B, Reichlin M. The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus. Clin Immunol Immunopathol 1998; 87:292.
  35. do Nascimento AP, Viana Vdos S, Testagrossa Lde A, et al. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum 2006; 54:1568.
  36. Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 2000; 59:99.
  37. Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007; 6:119.
  38. Ghirardello A, Doria A, Zampieri S, et al. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis 2000; 59:975.